FDA Ulcerative Colitis Guidance: 'Ideal' Vision Vs. Practical Interim Approach
Executive Summary
Agency favors assessments of signs/symptoms and endoscopy findings using well-defined and reliable patient- and clinician-reported outcomes instruments; since these don't exist, FDA will allow tweaking of existing assessment tools in the interim.
You may also be interested in...
Pfizer Eyes Xeljanz Expansion To Ulcerative Colitis
Pfizer Inc. released positive Phase III data from two induction trials testing its oral Janus kinase inhibitor Xeljanz (tofacitinib) in patients with the inflammatory bowel disease ulcerative colitis, but the company will await the results of another Phase III maintenance study before filing for an indication expansion.
Past Trials Can Provide Score For Temporary Ulcerative Colitis Endpoint, FDA Told
Changes in how efficacy of ulcerative colitis drugs are measured are coming, but FDA GREAT2 workshop focused on criteria to use in the interim. An academic/industry consortium plans to submit proposed patient-reported outcome questionnaires for UC and Crohn’s disease to the agency Dec. 20.
Pediatric IBD Studies Should Assess Disease Activity, Panel Says
Clinicians tell FDA that focusing solely on symptoms as an endpoint for pediatric ulcerative colitis and Crohn’s disease ignores the long-term deleterious effects of inflammation. Panel stresses the need to include growth as an endpoint and to conduct pediatric studies earlier.